Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib
Multiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-03-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/6295 |
| _version_ | 1797936234947936256 |
|---|---|
| author | Naveed Ali Peter V. Pickens Herbert E. Auerbach |
| author_facet | Naveed Ali Peter V. Pickens Herbert E. Auerbach |
| author_sort | Naveed Ali |
| collection | DOAJ |
| description | Multiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic myeloproliferative disorder of pluripotent hematopoietic stem cell, which is characterized by the uncontrolled proliferation of myeloid cells. An 88-year-old male was diagnosed simultaneously with IgD kappa MM and CML. A distinctive feature in this patient was the progression to plasma cell leukemia without any symptomatic myeloma stage. He was treated simultaneously with lenalidomide, bortezomib and imatinib. Synchronous occurrence of these rare hematological malignancies in a single patient is an exceedingly rare event. Multiple hypotheses to explain co-occurrence of CML and MM have been proposed; however, the exact etiological molecular pathophysiology remains elusive. |
| first_indexed | 2024-04-10T18:26:31Z |
| format | Article |
| id | doaj.art-4d087715248549fbaee199b8ba70700a |
| institution | Directory Open Access Journal |
| issn | 2038-8322 2038-8330 |
| language | English |
| last_indexed | 2024-04-10T18:26:31Z |
| publishDate | 2016-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-4d087715248549fbaee199b8ba70700a2023-02-02T05:24:38ZengMDPI AGHematology Reports2038-83222038-83302016-03-018110.4081/hr.2016.62953277Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinibNaveed Ali0Peter V. Pickens1Herbert E. Auerbach2Department of Internal Medicine, Abington Memorial Hospital/Abington-Jefferson Health, PADepartment of Hematology and Oncology, Abington Memorial Hospital/Abington Jefferson Health, PADepartment of Pathology, Abington Memorial Hospital/Abington-Jefferson Health, PAMultiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic myeloproliferative disorder of pluripotent hematopoietic stem cell, which is characterized by the uncontrolled proliferation of myeloid cells. An 88-year-old male was diagnosed simultaneously with IgD kappa MM and CML. A distinctive feature in this patient was the progression to plasma cell leukemia without any symptomatic myeloma stage. He was treated simultaneously with lenalidomide, bortezomib and imatinib. Synchronous occurrence of these rare hematological malignancies in a single patient is an exceedingly rare event. Multiple hypotheses to explain co-occurrence of CML and MM have been proposed; however, the exact etiological molecular pathophysiology remains elusive.http://www.pagepress.org/journals/index.php/hr/article/view/6295Immunoglobulin D multiple myelomaplasma cell leukemiachronic myelogenous leukemiabortezomibimatinib |
| spellingShingle | Naveed Ali Peter V. Pickens Herbert E. Auerbach Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib Hematology Reports Immunoglobulin D multiple myeloma plasma cell leukemia chronic myelogenous leukemia bortezomib imatinib |
| title | Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib |
| title_full | Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib |
| title_fullStr | Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib |
| title_full_unstemmed | Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib |
| title_short | Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib |
| title_sort | immunoglobulin d multiple myeloma plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide bortezomib dexamethasone and imatinib |
| topic | Immunoglobulin D multiple myeloma plasma cell leukemia chronic myelogenous leukemia bortezomib imatinib |
| url | http://www.pagepress.org/journals/index.php/hr/article/view/6295 |
| work_keys_str_mv | AT naveedali immunoglobulindmultiplemyelomaplasmacellleukemiaandchronicmyelogenousleukemiainasinglepatienttreatedsimultaneouslywithlenalidomidebortezomibdexamethasoneandimatinib AT petervpickens immunoglobulindmultiplemyelomaplasmacellleukemiaandchronicmyelogenousleukemiainasinglepatienttreatedsimultaneouslywithlenalidomidebortezomibdexamethasoneandimatinib AT herberteauerbach immunoglobulindmultiplemyelomaplasmacellleukemiaandchronicmyelogenousleukemiainasinglepatienttreatedsimultaneouslywithlenalidomidebortezomibdexamethasoneandimatinib |